ARTICLE | Clinical News
Summit preclinical data
July 25, 2011 7:00 AM UTC
In a human cell model of tauopathy, Summit's Seglin O-linked N-acetylglucosaminidase (O-GlcNAcase) inhibitors significantly reduced tau phosphorylation vs. both vehicle-treated and positive controls....